R&D Day Oct 2024: Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases (fddb85)

Published: 2025-05-16 05:18:04 ET VERA

Published on 05/16/2025 at 05:18

October 2, 2024

© 2024 VERA THERAPEUTICS, INC.

Opening Remarks

Marshall Fordyce, MD

Founder and CEO, Vera Therapeutics

Vera Expansion Strategy

Robert Brenner, MD

Chief Medical Officer, Vera Therapeutics

Q&A Panel

Jonathan Barratt, MD, PhD, FRCP

Mayer Professor of Renal Medicine, University of Leicester

Richard Lafayette, MD, FACP

Professor of Medicine (Nephrology), Stanford University Medical Center

Director, Stanford Glomerular Disease Center

Brad Rovin, MD, FACP, FASN

Lee A. Herbert Professor of Nephrology

Ohio State University Wexner Medical Center

Closing Remarks

Marshall Fordyce, MD

Founder and CEO, Vera Therapeutics

IgAN Potential First-in-Class Indication Expansion Resourced for Potential Launch

eGFR normalization may suggest disease modification

Only program with 2-yr data in Phase 2

 potential for commercial

differentiation, if approved

Only investigational drug with at home self administration of 1 mL QW and

>90% patient retention at 1.5 yr

Phase 3 read out on track for Q2 2025;

if successful, anticipated PDUFA 2026

B cell modulation represents a treatment paradigm shift for autoimmune diseases

Atacicept clinical data to date supports

potential for chronic administration

Progressive expansion in addressable patients: initial autoimmune kidney disease opportunity >200K

Additional potential upside in hematologic, rheumatologic, and other kidney indications

Regulatory exclusivity expected through 2038 in US and 2037 in EU

Currently ~$384M cash, cash equivalents and marketable securities as of June 30, 2024

Management focused on potential for successful commercial launch

BAFF = B cell activating factor; APRIL = A proliferation inducing ligand; eGFR = estimated glomerular filtration rate; IgAN = IgA nephropathy; SC = subcutaneous.

US prevalence estimates

~160K1

and Expanded IgAN

+ ~70 1-10

Non-IgAN autoimmune kidney disease

pMN, FSGS, MCD

Hematology

ITP, AIHA, CAD, APS

Rheumatology

SLE, Sjogren's, Long COVID

Neurology

MG

Metabolism

DM e 1

Vera Therapeutics corporate estimates for peak year prevalence based on 1. ClearView Healthcare Partners Analysis; 2. US Census 2023; 3. McGrogan A. Nephrol Dial Transplant 2011; 4. Couser ASN 2017; 5. Beck LH. N Engl J Med 2009; 6. Filler G. Am J Kidney Dis 2003; 7. Troyanov S. J Am Soc Nephrol 2005. 8. Hommos MS. Mayo Clin Proc 2017; 9. Hengel FE. N Engl J Med 2024; 10. Vivarelli M. Clin J Am Soc Nephrol 2017.

pMN = primary membranous nephropathy; FSGS = focal segmental glomerulosclerosis; MCD = minimal change disease; ITP = immune thrombocytopenia; AIHA = autoimmune hemolytic anemia; CAD = cold agglutinin disease; APS =

Disclaimer

Vera Therapeutics Inc. published this content on May 16, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 16, 2025 at 09:17 UTC.